CO2022009561A2 - Métodos de tratamiento de los trastornos asociados a la vía del receptor de melanocortina 4 - Google Patents
Métodos de tratamiento de los trastornos asociados a la vía del receptor de melanocortina 4Info
- Publication number
- CO2022009561A2 CO2022009561A2 CONC2022/0009561A CO2022009561A CO2022009561A2 CO 2022009561 A2 CO2022009561 A2 CO 2022009561A2 CO 2022009561 A CO2022009561 A CO 2022009561A CO 2022009561 A2 CO2022009561 A2 CO 2022009561A2
- Authority
- CO
- Colombia
- Prior art keywords
- melanocortin
- treatment methods
- disorders associated
- receptor pathway
- receptor
- Prior art date
Links
- 102000001796 Melanocortin 4 receptors Human genes 0.000 title abstract 4
- 108010021436 Type 4 Melanocortin Receptor Proteins 0.000 title abstract 4
- 230000037361 pathway Effects 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 206010020710 Hyperphagia Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Peptides Or Proteins (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063082867P | 2020-09-24 | 2020-09-24 | |
| PCT/US2021/052032 WO2022067086A1 (en) | 2020-09-24 | 2021-09-24 | Methods of treating melanocortin-4 receptor pathway-associated disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022009561A2 true CO2022009561A2 (es) | 2022-07-19 |
Family
ID=80845850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0009561A CO2022009561A2 (es) | 2020-09-24 | 2022-07-07 | Métodos de tratamiento de los trastornos asociados a la vía del receptor de melanocortina 4 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240058414A1 (https=) |
| EP (1) | EP4216979A4 (https=) |
| JP (1) | JP2023542985A (https=) |
| KR (1) | KR20230095956A (https=) |
| CN (1) | CN116507353A (https=) |
| AR (1) | AR123603A1 (https=) |
| AU (1) | AU2021350017A1 (https=) |
| CA (1) | CA3192873A1 (https=) |
| CL (1) | CL2023000823A1 (https=) |
| CO (1) | CO2022009561A2 (https=) |
| MX (1) | MX2023003360A (https=) |
| TW (1) | TW202228760A (https=) |
| WO (1) | WO2022067086A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4554607A2 (en) * | 2022-07-12 | 2025-05-21 | Rhythm Pharmaceuticals, Inc. | Methods for treating obesity with an mc4r agonist |
| WO2024108198A2 (en) * | 2022-11-18 | 2024-05-23 | Rhythm Pharmaceuticals, Inc. | Methods of treating obesity with an mc4r agonist |
| TW202535448A (zh) * | 2023-11-14 | 2025-09-16 | 美商律森製藥股份有限公司 | 鉀通道活化劑與mc4r促效劑之組合及相關使用方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ565217A (en) * | 2005-07-08 | 2010-03-26 | Ipsen Pharma Sas | Melanocortin receptor ligands |
| EP2970388B1 (en) * | 2013-03-15 | 2018-07-25 | Rhythm Pharmaceuticals, Inc. | Peptide compositions |
| PL3356386T3 (pl) * | 2015-09-30 | 2024-08-05 | Rhythm Pharmaceuticals, Inc. | Sposób leczenia zaburzeń związanych ze szlakiem receptora melanokortyny 4 |
-
2021
- 2021-09-24 AU AU2021350017A patent/AU2021350017A1/en active Pending
- 2021-09-24 US US18/028,117 patent/US20240058414A1/en active Pending
- 2021-09-24 MX MX2023003360A patent/MX2023003360A/es unknown
- 2021-09-24 KR KR1020237013822A patent/KR20230095956A/ko active Pending
- 2021-09-24 CA CA3192873A patent/CA3192873A1/en active Pending
- 2021-09-24 TW TW110135665A patent/TW202228760A/zh unknown
- 2021-09-24 CN CN202180071771.8A patent/CN116507353A/zh active Pending
- 2021-09-24 JP JP2023518779A patent/JP2023542985A/ja active Pending
- 2021-09-24 WO PCT/US2021/052032 patent/WO2022067086A1/en not_active Ceased
- 2021-09-24 AR ARP210102664A patent/AR123603A1/es unknown
- 2021-09-24 EP EP21873549.6A patent/EP4216979A4/en active Pending
-
2022
- 2022-07-07 CO CONC2022/0009561A patent/CO2022009561A2/es unknown
-
2023
- 2023-03-22 CL CL2023000823A patent/CL2023000823A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021350017A9 (en) | 2024-10-03 |
| TW202228760A (zh) | 2022-08-01 |
| KR20230095956A (ko) | 2023-06-29 |
| EP4216979A4 (en) | 2024-11-06 |
| AU2021350017A1 (en) | 2023-05-04 |
| US20240058414A1 (en) | 2024-02-22 |
| CA3192873A1 (en) | 2022-03-31 |
| CN116507353A (zh) | 2023-07-28 |
| EP4216979A1 (en) | 2023-08-02 |
| MX2023003360A (es) | 2023-06-23 |
| AR123603A1 (es) | 2022-12-21 |
| WO2022067086A1 (en) | 2022-03-31 |
| CL2023000823A1 (es) | 2023-09-15 |
| JP2023542985A (ja) | 2023-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022009561A2 (es) | Métodos de tratamiento de los trastornos asociados a la vía del receptor de melanocortina 4 | |
| CL2022001256A1 (es) | Métodos y composiciones para tratar un trastorno asociado con el angiotensinogeno agt | |
| MX2021013197A (es) | Cicloalquilos sustituidos como moduladores de la vía integrada del estrés. | |
| CY1125423T1 (el) | Μεθοδος in vitro διαφοροποιησης των μεσεγκεφαλικων ντοπαμινεργικων(mda)νευρωνων | |
| CO2021005231A2 (es) | Composiciones y métodos para la edición génica de lactato deshidrogenasa (ldha) | |
| CL2016002998A1 (es) | Aparatos de tratamiento de líquido electroquímico | |
| MX2021008364A (es) | Amidas de pirrolidina iii sustituidas. | |
| MX2018014911A (es) | Metodos para el tratamiento de afecciones malignas de celulas t usando terapia de celulas adoptivas. | |
| CO2020005417A2 (es) | Inhibidores de la quinasa p38 que reducen la expresión de dux4 y de los genes corriente abajo para el tratamiento de fshd | |
| MX375746B (es) | Combinación de lenalidomida y constructo de polipéptido, y sus usos. | |
| MX383296B (es) | Vigilancia del tratamiento y pronóstico de los trastornos de la proliferación utilizando inhibidores de la vía de hedgehog. | |
| PH12017502120A1 (en) | A method and an apparatus for forming a lignin fraction, a lignin composition and its use | |
| EA201000673A1 (ru) | СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ИЗМЕРЕНИЯ АКТИВАЦИИ Wnt И ДЛЯ ЛЕЧЕНИЯ Wnt-ОПОСРЕДОВАННЫХ РАКОВЫХ ЗАБОЛЕВАНИЙ | |
| CL2025000071A1 (es) | Métodos para tratar la obesidad con un agonista de mc4r | |
| UY32449A (es) | Benzazepinas fusionadas como ligandos de receptor de acetilcolina nicotínico neuronal | |
| CL2021001903A1 (es) | Tratamiento de la hepatotoxicidad | |
| MX388890B (es) | Metodos para tratar cancer usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton. | |
| AR087731A1 (es) | Metodo para tratar crecimiento celular anormal | |
| CL2023003126A1 (es) | Métodos de identificación de pacientes con posibilidad de beneficiarse de tratamiento con inhibidor de telomerasa | |
| CL2025002297A1 (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa. | |
| AR100734A1 (es) | Método para tratar leucemia linfocítica crónica (cll) | |
| CL2024003486A1 (es) | Anticuerpo anti-b7h3 y usos del mismo | |
| CL2024000370A1 (es) | Composiciones y métodos para el tratamiento de cáncer. | |
| MX2022012302A (es) | Formas polimórficas de metopimazina novedosas. | |
| BR112021018528A2 (pt) | Uso de moduladores do receptor gabaa para tratamento de dor |